Single-agent (N = 20) | Platinum doublet (N = 11) | |
---|---|---|
Regimen | ||
Gemcitabine | 8 (40.0%) | 0 |
Vinorelbine | 6 (30.0%) | 0 |
Docetaxel | 5 (25.0%) | 0 |
Pemetrexed | 1 (5.0%) | 0 |
Carboplatin + weekly paclitaxel | 0 | 9 (81.8%) |
Carboplatin + gemcitabine | 0 | 1 (9.1%) |
Carboplatin + S-1 | 0 | 1 (9.1%) |
Response rate (%) | 0 | 45.4% |
Disease control rate (%) | 55.0% | 54.5% |
Progression free survival (month) | 2.87 [0.60–7.27] | 5.43 [1.58–8.07] |
Number of treatment cycles | 2.00 [1.00–2.25] | 3.00 [1.00–4.00] |
Early termination (only 1 cycle) (%) | 7 (35.0%) | 4 (36.4%) |
Cause of cessation | ||
Adverse event | 11 (55.0%) | 4 (36.4%) |
Deterioration of physical condition | 5 (25.0%) | 0 |
Completion of 4–6 cycles | 0 | 5 (45.5%) |
Progressive disease | 3 (15.0%) | 1 (9.1%) |
Patient’s request | 1 (5.0%) | 1 (9.1%) |